Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-27T12:07:44.250Z Has data issue: false hasContentIssue false

Chapter 13 - Treatment of Hemifacial Spasm with Botulinum Toxin

Published online by Cambridge University Press:  02 November 2023

Daniel Truong
Affiliation:
University of California, Riverside
Dirk Dressler
Affiliation:
Hannover Medical School
Mark Hallett
Affiliation:
National Institutes of Health (NIH)
Christopher Zachary
Affiliation:
University of California, Irvine
Mayank Pathak
Affiliation:
Truong Neuroscience Institute
Get access

Summary

PP> Hemifacial spasm (HFS) consists of involuntary irregular clonic or tonic twitch-like movements of the facial muscles innervated by cranial nerve VII on one side of the face, and is most often a result of vascular compression of the facial nerve at the root exit/entry zone. Non-vascular causes of HFS are less common, and include facial nerve injury, Bell’s palsy, demyelination presumed to involve the facial nucleus and various tumors and space-occupying lesions in the cerebellopontine angle. PP> Twitches usually begin in the periocular region and can progress to the cheek, perioral and platysma muscles. Hemifacial spasm is almost always unilateral. Muscles involved in HFS include the orbicularis oculi, orbicularis oris and zygomaticus predominantly with frontalis, corrugator, nasalis, buccinators, risorius, depressor angularis oris, mentalis and platysma. PP> Injections of botulinum neurotoxin (BoNT) are the preferred treatment of HFS. They are successful in over 90% of patients, with relief lasting approximately 12 weeks, and repeat treatments remaining effective for many years. This chapter lists the pertinent facial muscles along with their principal mechanical actions; illustrates their anatomy under the skin, showing the recommended injection sites; and tabulates the dose ranges of the various toxins in each of the muscles. <COMP: I can’t get rid of the PP coding here without seeming to lose text>

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cannon, PS, MacKenzie, KR, Cook, AE, Leatherbarrow, B (2010). Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm. Clin Exp Ophthalmol, 38, 688–91.Google Scholar
Colakoglu, BD, Cakmur, R, Uzunel, F (2011). Is it always necessary to apply botulinum toxin into the lower facial muscles in hemifacial spasm? A randomized, single-blind, crossover trial. Eur Neurol, 65, 286–90.CrossRefGoogle ScholarPubMed
Elston, JS (1986). Botulinum toxin treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry, 49, 827–9.CrossRefGoogle ScholarPubMed
Elston, JS (1992). The management of blepharospasm and hemifacial spasm. J Neurol, 239, 58.CrossRefGoogle ScholarPubMed
Frei, K, Truong, DD, Dressler, D (2006). Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations. Eur J Neurol, 13(Suppl 1), 30–5.CrossRefGoogle ScholarPubMed
Linder, JS, Edmonson, BC, Laquis, SJ, Drewry, RD, Jr., Fleming, JC (2002). Skin cooling before periocular botulinum toxin A injection. Ophthal Plast Reconstr Surg, 18, 441–2.CrossRefGoogle ScholarPubMed
Mercier, P, Sindou, M (2018). The conflicting vessels in hemifacial spasm: Literature review and anatomical-surgical implications. Neurochirurgie, 64, 94100.CrossRefGoogle ScholarPubMed
Mezaki, T, Kaji, R, Kimura, J, Ogawa, N (1999). Treatment of hemifacial spasm with type A botulinum toxin (AGN 191622): a dose finding study and the evaluation of clinical effect with electromyography. No To Shinkei, 51, 427–32.Google ScholarPubMed
Miwa, H, Mizuno, Y, Kondo, T (2002). Familial hemifacial spasm: report of cases and review of the literature. J Neurol Sci, 193, 97102.Google Scholar
Ozzello, DJ, Giacometti, JN (2018). Botulinum toxins for treating essential blepharospasm and hemifacial spasm. Int Ophthalmol Clin, 58, 4961.Google Scholar
Price, J, Farish, S, Taylor, H, O’Day, J (1997). Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology, 104, 865–8.Google ScholarPubMed
Roggenkamper, P, Laskawi, R, Damens, W, Schroeder, M, Nuessgens, Z (1994). Orbicular synkinesis after facial paralysis: treatment with botulinum toxin. Doc Ophthalmol, 86, 395402.CrossRefGoogle ScholarPubMed
Rudzinska, M, Wojcik, M, Szczudilik, A (2010). Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy. J Neural Transm, 117, 765–72.CrossRefGoogle ScholarPubMed
Ryu, H, Yamamoto, S, Miyamoto, T (1998). Atypical hemifacial spasm. Acta Neurochir (Wien), 140, 1173–6.CrossRefGoogle ScholarPubMed
Sindou, M, Mercier, P (2018). Microvascular decompression for hemifacial spasm: Outcome on spasm and complications: a review. Neurochirurgie, 64, 106–16.CrossRefGoogle ScholarPubMed
Tousi, B, Perumal, JS, Ahuja, K, Ahmed, A, Subramanian, T (2004). Effects of botulinum toxin-B (BTX-B) injections for hemifacial spasm. Parkinsonism Relat Disord, 10, 455–6.CrossRefGoogle ScholarPubMed
Wang, A, Jankovic, J (1998). Hemifacial spasm: clinical findings and treatment. Muscle Nerve, 21, 1740–7.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
Yalto, TC, Jankovic, J (2011). The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord, 26, 1582–92.Google Scholar
Yoshimura, DM, Aminoff, MJ, Tami, TA, Scott, AB (1992). Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve, 15, 1045–9.CrossRefGoogle ScholarPubMed
Yu, YL, Fong, KY, Chang, CM (1992). Treatment of idiopathic hemifacial spasm with botulinum toxin. Acta Neurol Scand, 85, 55–7.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×